Publications by authors named "Masaharu Doi"

2 Publications

  • Page 1 of 1

Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients.

J Dermatol 2017 Nov 9;44(11):1212-1218. Epub 2017 Aug 9.

Data Science Department, Maruho Co. Ltd, Kyoto, Japan.

Benzoyl peroxide (BPO) has been well established as a common medication for acne vulgaris in many countries (e.g. in Europe and the USA), where clinical data have been accumulated over a long time. In Japan, the use of BPO for acne treatment was approved in 2014, and the results of clinical trials in Japanese patients have recently been reported. This review compares clinical study results between Japanese and Western patients. Clinical studies that had been performed in Western countries were searched on the basis of the criteria, double-blind studies of BPO monotherapy and comparison with a vehicle group. Two reports of Japanese studies were also selected by using the same criteria. Efficacy was assessed by comparing the mean difference between the BPO and the vehicle groups for reduction rate in the number of lesions from baseline, and there were no differences between Japanese and Western patients. Safety assessment also showed that the incidence of adverse events was higher in Japanese patients than in Western patients, but the characteristics of the adverse events were not different. Therefore, we conclude that there are no significant differences in the efficacy and safety of BPO between these patient populations. The efficacy and safety of long-term use in Japanese patients are also expected to be applicable to those in Western patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.13996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697687PMC
November 2017

Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins.

Int J Pharm 2004 May;275(1-2):239-48

Pharmacy Laboratories, Nippon Shinyaku Co. Ltd., 14, Nishinosho-Monguchicho, Kissyoin, Minami-Ku, Kyoto 601-8550, Japan.

Nanometer-sized lipid emulsion particles with a diameter of 25-50 nm, called Lipid Nano-Sphere (LNS), are expected as a promising drug carrier to show prolonged plasma half-life of an incorporating drug. In terms of successful drug delivery using LNS, a drug should be incorporated into the lipid particles and remain within the particle, not only in the formulation in vitro but also after administration into the systemic blood circulation. In this study, we showed that phospholipids and some water-insoluble molecules also moved from lipid particles to plasma lipoproteins or albumin in serum and plasma half-lives of these compounds did not reflect that of the drug carriers. It was suggested that phospholipid or its derivative were transferred from LNS particles to plasma lipoproteins by lipid transfer proteins (LTP) in the circulation. These phenomena leaded to unsuccessful delivery of the drug with lipid-particulate drug carriers. On the other hand, lipophilic derivatives with cholesterol pro-moiety tested in this study were not released from LNS particles and showed prolonged plasma half-lives. Lipophilicity is known to be an important parameter for incorporating drugs into lipid particles but substrate specificity for LTP seems to be another key to success promising drug design using lipid emulsion particulate delivery system.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2004.02.008DOI Listing
May 2004